Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2011

View Archived Issues

Dutasteride reduces risk of prostate cancer in men with small prostates

Denosumab delays pain interference in patients with CRPC

RespiVent reports new PI3K-delta inhibitors

Canadian researchers present new polypeptide PTEN inhibitors

FDA advisory committee recommends retention of indication for Abbott's Trilipix

S-APP-alpha is a possible biomarker in fragile X syndrome and autism

Gamma-sarcoglycan gene therapy safe in patients with limb girdle muscular dystrophy type 2C

ZIOPHARM Oncology files IND application for phase I Ad-RTS-IL-12 trial in melanoma

GSK prepares novel agents for HCV infection

Spanish researchers disclose new acetylcholinesterase inhibitors

New modulators of metabotropic glutamate mGlu4 receptor claimed

New selective adenosine A2A receptor antagonists patented

FDA clears Repligen's phase I trial of RG-3039 for spinal muscular atrophy

Medivir reports 48-week interim results from ASPIRE phase IIb trial of TMC-435

CHMP recommends conditional marketing authorization of Fampyra

Study of Actelion's prostanoid DP2 receptor antagonist in allergic rhinitis meets primary endpoint

GSK and Human Genome Sciences receive CHMP positive opinion for Benlysta

European Commission approves Eliquis for prevention of VTE after hip or knee replacement

CHMP recommends approval of Vibativ for nosocomial pneumonia caused by MRSA

Pfizer receives FDA approval for Sutent in advanced pancreatic neuroendocrine tumors

Auxilium Pharmaceuticals receives payment after launching Xiapex in Germany

Phase II data disclosed on fulranumab in low back and osteoarthritic pain

EMA committee recommends accelerated approval of Victrelis for hepatitis C genotype 1

PharmaGap's anticancer candidate GAP-107B8 shows improved potency and bioavailability in liposomes

Viralytics receives FDA reply regarding clinical hold on phase II Cavatek trial in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...